Content area

Abstract

Predicting drug–target interaction is key for drug discovery. Recent deep learning-based methods show promising performance, but two challenges remain: how to explicitly model and learn local interactions between drugs and targets for better prediction and interpretation and how to optimize generalization performance of predictions on novel drug–target pairs. Here, we present DrugBAN, a deep bilinear attention network (BAN) framework with domain adaptation to explicitly learn pairwise local interactions between drugs and targets, and adapt in response to out-of-distribution data. DrugBAN works on drug molecular graphs and target protein sequences to perform prediction, with conditional domain adversarial learning to align learned interaction representations across different distributions for better generalization on novel drug–target pairs. Experiments on three benchmark datasets under both in-domain and cross-domain settings show that DrugBAN achieves the best overall performance against five state-of-the-art baseline models. Moreover, visualizing the learned bilinear attention map provides interpretable insights from prediction results.

Predicting drug–target interaction with computational models has attracted a lot of attention, but it is a difficult problem to generalize across domains to out-of-distribution data. Bai et al. present here a method that aims to model local interactions of proteins and drug molecules while being interpretable and provide cross-domain generalization.

Details

Title
Interpretable bilinear attention network with domain adaptation improves drug–target prediction
Author
Bai, Peizhen 1   VIAFID ORCID Logo  ; Miljković, Filip 2   VIAFID ORCID Logo  ; John, Bino 3 ; Lu, Haiping 1   VIAFID ORCID Logo 

 University of Sheffield, Department of Computer Science, Sheffield, UK (GRID:grid.11835.3e) (ISNI:0000 0004 1936 9262) 
 Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Imaging and Data Analytics, Gothenburg, Sweden (GRID:grid.418151.8) (ISNI:0000 0001 1519 6403) 
 Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Imaging and Data Analytics, Waltham, USA (GRID:grid.418152.b) (ISNI:0000 0004 0543 9493) 
Pages
126-136
Publication year
2023
Publication date
Feb 2023
Publisher
Nature Publishing Group
e-ISSN
25225839
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2778815938
Copyright
© The Author(s), under exclusive licence to Springer Nature Limited 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.